GTBP vs. SNPX, SEEL, EIGR, LGVN, PHXM, KPRX, EDSA, BIVI, XCUR, and FRTX
Should you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Synaptogenix (SNPX), Seelos Therapeutics (SEEL), Eiger BioPharmaceuticals (EIGR), Longeveron (LGVN), PHAXIAM Therapeutics (PHXM), Kiora Pharmaceuticals (KPRX), Edesa Biotech (EDSA), BioVie (BIVI), Exicure (XCUR), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "medical" sector.
Synaptogenix (NASDAQ:SNPX) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.
GT Biopharma has a consensus target price of $150.00, suggesting a potential upside of 4,043.65%. Given Synaptogenix's higher probable upside, analysts clearly believe GT Biopharma is more favorable than Synaptogenix.
GT Biopharma received 114 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 62.84% of users gave GT Biopharma an outperform vote while only 50.00% of users gave Synaptogenix an outperform vote.
Synaptogenix has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.
In the previous week, Synaptogenix had 2 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for Synaptogenix and 1 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.
GT Biopharma's return on equity of -22.50% beat Synaptogenix's return on equity.
GT Biopharma is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.
10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 8.1% of GT Biopharma shares are held by institutional investors. 4.3% of Synaptogenix shares are held by company insiders. Comparatively, 10.0% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Synaptogenix beats GT Biopharma on 7 of the 13 factors compared between the two stocks.
Get GT Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GT Biopharma Competitors List
Related Companies and Tools
